Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 2/20 | 0.46 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.46 |
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 2/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL46328 | 0.82 | L3MBTL1 (0.49) | PCSK9CNR2PIM1PIM3PIM2 | |
| SCHEMBL16498074 | 0.81 | CNR2 (0.44) | PCSK9CNR2PIM1PIM3PIM2 | |
| SCHEMBL12963895 | 0.78 | PCSK9 (0.46) | PCSK9CNR2PIM1PIM3PIM2 | |
| SCHEMBL14910345 | 0.77 | CNR2 (0.53) | ALOX5APPCSK9FEN1CNR2PIM1 | |
| SCHEMBL10219975 | 0.77 | PCSK9 (0.43) | PCSK9CNR2PIM1PIM3PIM2 | |
| SCHEMBL22575228 | 0.77 | ALOX5AP (0.54) | ALOX5APFEN1CNR2PIM1PIM3 | |
| SCHEMBL30638502 | 0.75 | GAA (0.43) | PCSK9CNR2PIM1PARP1L3MBTL1 | |
| SCHEMBL20390820 | 0.75 | GAA (0.43) | PCSK9CNR2PIM1PARP1L3MBTL1 | |
| SCHEMBL22241810 | 0.75 | PCSK9 (0.69) | PCSK9CNR2PIM1PIM3PIM2 | |
| SCHEMBL18291480 | 0.75 | PIM1 (0.44) | ALOX5APFEN1PIM1PIM3PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220122-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2022-07-14 | — | — | US | disclosed |
| US-20160101104-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-14 | — | — | US | disclosed |
| US-20160101104-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-14 | — | — | US | disclosed |
| US-20160101104-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-14 | — | — | US | disclosed |
| US-20150342935-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150342935-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150342935-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2015-12-03 | — | — | US | disclosed |
| EP-2271650-B1 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20150094309-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-02 | — | — | US | disclosed |
| US-20150094309-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-02 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| WO-2009131926-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009131926-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-29 | — | — | WO | disclosed |
| US-7514439-B2 | Oxime derivative and preparations thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| US-7514439-B2 | Oxime derivative and preparations thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20080132479-A1 | Oxime Derivative and Preparations Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| US-20080132479-A1 | Oxime Derivative and Preparations Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| WO-2007007886-A1 | AN OXIME DERIVATIVE AND PREPARATIONS THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | ALOX5AP 3927/4885PCSK9 3278/4885FEN1 4615/4885 |
| US-20160101104-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | ALOX5AP 3927/4885PCSK9 3278/4885FEN1 4615/4885 |
| US-20080132479-A1 | Oxime Derivative and Preparations Thereof | GCK, KHK, GCKR | ALOX5AP 3013/4885PCSK9 3631/4885FEN1 4402/4885 |
| US-20150342935-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | ALOX5AP 3927/4885PCSK9 3278/4885FEN1 4615/4885 |
| US-20150094309-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | ALOX5AP 3927/4885PCSK9 3278/4885FEN1 4615/4885 |
| US-20220220122-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | ALOX5AP 573/4885PCSK9 1/4885FEN1 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.